Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Off-Label Reprint Guidance: “Definitely Improved,” But Will Waxman Fight On?

Executive Summary

FDA's finalized guidance on off-label reprints contains small modifications that appear to satisfy free speech critics of the draft version. But it does not offer sufficient change to mollify congressional critics who believe the document is too permissive

You may also be interested in...

FDA Reprint Policy Expands To Clinical Practice Guidelines, Medical Reference Texts

FDA has revised, but not loosened, its 2009 final guidance on good reprint practices for distribution of journal articles on unapproved uses of approved drugs and devices.

Journal Reprints Shouldn’t See The Light Of Sunshine, Medical Societies Say

Last-ditch effort to rewrite reg warns of unintended consequences from the reporting requirement.

Risperdal Marketing Settlement Prevents Reprint Distribution Without sNDA

J&J’s agreement with state AGs, which involves payments totaling $181 million, sets a number of restrictions on the company’s marketing practices for atypical antipsychotics that will be in effect for five years.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts